CURRENT REPORT BLOG The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the use of the Gardasil vaccine as a single dose for routine immunization against cervical cancer. This off-label use is set to commence in Nigeria in the last quarter of 2023. The single-dose approach offers several benefits, including cost-effectiveness, improved vaccine accessibility, and potentially hastening the elimination of cervical cancer as a public health concern.
Cervical cancer is a significant health issue in Nigeria due to low awareness, limited screening, and high HPV infection rates. The move is in line with a global strategy by the World Health Organization (WHO) to combat cervical cancer and improve healthcare access in Nigeria and other African countries.
